2022 Revenues ($USD) : $1,098,800,000
2022 R&D spend : $160,100,000
2022 Number of Employees : 2,300
Fiscal Year End : 12/31/2021
Company CEO : Jim Hollingshead, president and CEO

In January, Acton, Massachusetts–based Insulet’s Omnipod 5 became the first tubeless, wearable automated insulin delivery system cleared for marketing in the U.S. for people 6 years of age and older with type 1 diabetes. Omnipod 5 represents the latest innovation in the company’s portfolio of insulin pumps and has since received FDA clearance for people aged 2 years and older with type 1 diabetes. The company has also undergone a significant leadership change, as CEO Shacey Petrovic stepped down after more than three years in the corner office due to personal reasons. The company's board handed the reins over to Jim Hollingshead, the former president of sleep and respiratory care at ResMed. –SW